A brain cancer pathway in clinical practice.

Area of Science:

• Neuro-oncology
• Clinical pathway implementation
• Diagnostic accuracy

Background:

• Danish healthcare aims to enhance cancer survival rates through improved diagnostics, timely treatment, and proactive prevention.
• The Integrated Brain Cancer Pathway (IBCP) was developed to address these goals within neuro-oncology.
• This study evaluates the initial phase of the IBCP in a clinical setting, focusing on its inclusion criteria.

Purpose of the Study:

• To assess the effectiveness of the Integrated Brain Cancer Pathway's inclusion criteria in a real-world clinical setting.
• To determine the diagnostic performance of the IBCP criteria in identifying patients with brain malignancies.
• To analyze the initial phase of the IBCP and its impact on patient management.

Main Methods:

• A retrospective study included patients admitted to a regional neurology department over two years who met IBCP inclusion criteria.
• Data on onset symptoms, diagnosis, and diagnostic work-up time were collected and supplemented by patient record reviews.
• Sensitivity, specificity, and positive predictive values of the inclusion criteria were calculated using magnetic resonance imaging (MRI) of the cerebrum as the reference standard.

Main Results:

• The predictive strength of the IBCP inclusion criteria was influenced by the number and type of symptoms presented.
• The criteria successfully identified the majority of patients with symptomatic brain malignancy.
• The IBCP criteria demonstrated high predictive value for general structural brain lesions.

Conclusions:

• The implementation of the Integrated Brain Cancer Pathway represents a significant advancement in optimizing the care trajectory for brain cancer patients.
• The pathway's criteria are effective in identifying relevant patient populations for neuro-oncology assessment.
• The IBCP contributes to improved efficiency and accuracy in the diagnosis and management of brain tumors.